Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study.

Belhadj, K; Delfau-Larue, M-H; Elgnaoui, T; Beaujean, F; Beaumont, J-L; Pautas, C; Gaillard, I; Kirova, Y; Allain, A; Gaulard, P; Farcet, J-P; Reyes, F; Haioun, C

Belhadj, K; Delfau-Larue, M-H; Elgnaoui, T; Beaujean, F; Beaumont, J-L; Pautas, C; Gaillard, I; Kirova, Y; Allain, A; Gaulard, P; Farcet, J-P; Reyes, F; Haioun, C.

Afiliación

Belhadj K; CHU Henri Mondor, Service d'Hématologie Clinique, Creteil, France. karim.belhadj@hmn.ap-hop-paris.fr

Ann Oncol ; 15(3): 504-10, 2004 Mar.

Article en En | MEDLINE | ID: mdl-14998857

RESUMEN

BACKGROUND: Rituximab induces clinical response in advanced B-cell lymphoma and is efficient in removing circulating B-cell from peripheral blood. We therefore postulated that rituximab might be a useful in vivo purging agent before high-dose therapy in this setting. PATIENTS AND METHODS: Fourteen patients with relapsed follicular, marginal zone and mantle cell lymphomas (11, two and one cases, respectively) and a PCR-detectable molecular marker were treated first with rituximab, then a mobilization chemotherapeutic regimen, followed by high-dose therapy with peripheral blood stem cell transplantation. PCR analyses were performed in peripheral blood before rituximab and during follow-up, and in harvest. RESULTS: Harvests were free of PCR-detectable molecular marker in nine of the 11 studied cases (82%). After high-dose therapy, clinical complete remission was obtained in 13 (93%) patients and molecular remission in 11 (79%). With a median follow-up of 3 years, the 14 transplanted patients were alive, 11 of them remaining in clinical complete remission and eight in molecular remission at last follow-up. CONCLUSION: Rituximab treatment followed by high dose therapy appears to be effective in achieving complete clinical and molecular response. In vivo harvest purging is predictive of prolonged clinical and molecular remission.

Asunto(s)

Anticuerpos Monoclonales/uso terapéutico; Antineoplásicos/uso terapéutico; Purgación de la Médula Ósea/métodos; Linfoma de Células B/terapia; Linfoma Folicular/terapia; Linfoma de Células del Manto/terapia; Trasplante de Células Madre de Sangre Periférica; Adulto; Anticuerpos Monoclonales de Origen Murino; Antígenos CD34/metabolismo; Terapia Combinada; Femenino; Estudios de Seguimiento; Movilización de Célula Madre Hematopoyética; Humanos; Linfoma de Células B/patología; Linfoma Folicular/patología; Linfoma de Células del Manto/patología; Masculino; Persona de Mediana Edad; Recurrencia Local de Neoplasia/patología; Recurrencia Local de Neoplasia/terapia; Inducción de Remisión; Rituximab; Terapia Recuperativa; Células Madre/patología; Trasplante Autólogo; Resultado del Tratamiento

Buscar en Google

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma de Células B / Linfoma Folicular / Purgación de la Médula Ósea / Linfoma de Células del Manto / Trasplante de Células Madre de Sangre Periférica / Anticuerpos Monoclonales / Antineoplásicos Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2004 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido

Buscar en Google

Añadir a Mi BVS

Imprimir

XML

PubMed Links